Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2068-2076

  Walsh, Thomas J ^a   Jackson, Andre J ^b   Lee, James W ^a   Amantea, Michael ^a   Sein, Tin ^a   Bacher, John ^c   Zech, Loren ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Center for Drug Evaluation and Research   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANTIMICROBIAL THERAPY; ARTICLE; COMPARTMENT MODEL; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG INFUSION; DRUG METABOLISM; DRUG UPTAKE; FEMALE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RABBIT;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; LIPIDS; MODELS, BIOLOGICAL; RABBITS; REPRODUCIBILITY OF RESULTS;

EID: 0033943751     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2068-2076.2000     Document Type: Article

References (18)

1. Adamson, P. C., M. G. Rinaldi, P. A. Pizzo, and T. J. Walsh. 1989. Amphotericin B in treatment of Candida cholecystitis. Pediatr. Infect. Dis. J. 8:408-411.
2. Atkinson, A. J., and J. E. Bennett. 1978. Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13:271-276.
3. Bhamra, R., A. Sa'ad, L. E. Bolcsak, A. S. Janoff, and C. E. Swenson. 1997. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob. Agents Chemother. 41:886-892.
4. Bruno, R., N. Vivier, J. C. Vergniol, S. L. DePhillips, G. Montay, and L. B. Sheiner. 1996. A population pharmacokinetic model for doxcetaxel (Taxotere®): model building and validation. J. Pharmacokinet. Biopharm. 24:153-172.
5. Craven, P. C., T. M. Ludden, D. J. Drutz, W. Rogers, K. A. Haegek, and H. B. Skrdlant. 1979. Excretion pathways of amphotericin B. J. Infect. Dis. 140: 329-341.
6. de Marie, S. 1996. Liposomal and lipid-based formulations of amphotericin B. Leukemia 10(Suppl. 2):S93-S96.
7. Gough, K., M. H. Hutchison, O. Keene, B. Byrom, S. Elli, L. Lacey, and J. McKellar. 1995. Assessment of dose proportionality: report from the statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party. Drug Infect. J. 29:1039-1048.
8. Granich, G. G., G. S. Kobayashi, and D. J. Krogstad. 1986. Sensitive high pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob. Agents Chemother. 29:584-588.
9. Hiemenz, J. W. and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22:S133-S144.
10. Janoff, A. S., L. T. Boni, M. C. Popescu, S. R. Minchey, P. R. Cullis, T. D. Madden, T. Taraschl, S. M. Gruner, E. Shyarnsunder, and M. W. Tate. 1988. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA 85:6122-6126.
11. Mehta, R., G. Lopez-Berestein, R. Hopfer, K. Mills, and R. L. Juliano. 1984. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim. Biophys. Acta 770:230-4.
12. Palek, J. 1991. Red cell membrane disorders in hematology, p. 472-503. In R. Hoffman, E. J. Benz, Jr., S. J. Shattil, B. Furie, and H. Cohen (ed.), Basic principles and practice. Churchill Livingstone, Inc., New York, N.Y.
13. Sjanknegt, R., S. de Marie, I. A. J. M. Bakker-Woudenberg, and D. J. A. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clin. Pharmacokinet. 23:279-291.
14. Vartivarian, S. E., E. J. Anaissie, and G. P. Bodey. 1993. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis. 17(Suppl. 2):S487-S491.
15. Walsh, T. J., J. Hiemenz, and E. Anaissie. 1996. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect. Dis. Clin. N. Am. 10:365-400.
16. Walsh, T. J., J. Bachar, and P. A. Pizzo. 1988. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab. Anim. Med. 38:467-471.
17. Walsh, T. J., P. Whitcomb, S. Piscitelli, W. D. Figg, S. Hill, S. J. Chanock, P. Jarosinski, R. Gupta, and P. A. Pizzo. 1997. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents Chemother. 41:1944-1948.
18. Weisbroth, H., and R. E. Flatt. 1974. The biology of the laboratory rabbit, p. 57. Kraus Academic Press, New York, N.Y.